During Q2, several companies operating in the Life Science Tools and Services (LSTS) industry encountered obstacles due to the economic downturn in China and the restrained spending habits of biopharma clients in Europe and the US. These factors have the potential to continue impacting revenue and margins. Nevertheless, the industry still offers hopeful prospects despite its lower performance compared to the broader market. In this recording, CFRA Research Vice President of Equity Research Sel Hardy sheds light on the challenging business climate, existing challenges and potential benefits, and the winners and losers in the life science sector.